View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 18, 2021updated 11 Jul 2022 2:17pm

Janssen reports positive Phase II data from Crohn’s disease therapy trial

In the trial, 65% of participants who received Tremfya treatment attained clinical remission at week 48. 

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported positive data from the Phase II GALAXI 1 trial of Tremfya (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), an inflammatory bowel disease.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A fully human monoclonal antibody developed by Janssen, Tremfya can specifically attach to the p19 subunit of interleukin-23 (IL-23) preventing it from interacting with the IL-23 receptor.

The company noted that IL-23 is a key driver of inflammatory disease pathogenesis.

The double-blind, multicentre, placebo-controlled, dose-ranging trial is analysing the efficacy and safety of Tremfya in CD patients who have had insufficient response or tolerance to standard treatments and/or biologics.

Subjects were randomised into five arms to receive either a 200mg, 600mg or 1,200mg intravenous dose of Tremfya at 0, 4 and 8 weeks, respectively, or ustekinumab or placebo.

The change from baseline in Crohn’s Disease Activity Index (CDAI) scores at week 12 was the primary goal of the trial.

Clinical response and remission, patient report outcome-2 remission, clinical biomarker response, endoscopic response and safety in subjects receiving Tremfya versus placebo, were the other crucial outcomes assessed at week 12.

The latest findings from the trial showed that the rates of clinical remission reported at week 12 rose at week 48 in the subjects treated with Tremfya.

Furthermore, 65% of subjects in Tremfya arms attained clinical remission at week 48.

During the 48-week treatment duration, all Tremfya treatment arms had similar safety data, which were also in line with the already reported safety profile of the drug.

The Phase III trials of Tremfya underway to treat moderately to severely active CD, as well as moderately to severely active ulcerative colitis, are currently enrolling subjects.

Janssen Research & Development Gastroenterology Disease Area Leader vice-president Jan Wehkamp said: “We look forward to sharing the comprehensive GALAXI 1 48-week results at an upcoming scientific medical meeting while we continue to progress and enrol patients in the pivotal Phase III GALAXI 2 and 3 studies.”

Earlier this month, Janssen reported positive data from the Phase III trial of Tremfya for the treatment of active psoriatic arthritis.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena